Astrazeneca (AZN) Revenue (2009 - 2026)

Astrazeneca has reported Revenue for 18 years, with the latest figure at $15.4 billion in Q2 2026.

• On a quarterly basis, Revenue rose 6.47% year-over-year to $15.4 billion in Q2 2026; TTM through Jun 2026 was $61.3 billion, a 10.31% increase from a year earlier, with the FY2025 full-year figure at $58.6 billion, up 10.33% from the prior year.
• Revenue was $15.4 billion for Q2 2026 at Astrazeneca, up from $15.2 billion in the prior quarter.
• The five-year high for Revenue was $32.5 billion in Q4 2023, with the low at $10.6 billion in Q1 2023.
• Average Revenue over 5 years is $14.0 billion, with a median of $13.2 billion recorded in 2024.
• The sharpest annual moves came in 2023 and 2024: Revenue soared 189.69% in 2023, then slumped 56.64% in 2024.
• Over 5 years, Revenue stood at $11.2 billion in 2022, then jumped by 189.69% to $32.5 billion in 2023, then sank by 56.64% to $14.1 billion in 2024, then gained by 10.1% to $15.5 billion in 2025, then dropped by 0.73% to $15.4 billion in 2026.
• The last three Revenue figures came in at $15.4 billion (Q2 2026), $15.2 billion (Q1 2026), and $15.5 billion (Q4 2025), per Business Quant data.